How were Juno Therapeutics' earnings last quarter?

Juno Therapeutics Inc (NASDAQ:JUNO) announced its earnings results on Wednesday, November, 1st. The biopharmaceutical company reported ($0.73) EPS for the quarter, beating analysts' consensus estimates of ($0.80) by $0.07. The biopharmaceutical company had revenue of $44.80 million for the quarter, compared to analyst estimates of $18.12 million. Juno Therapeutics's quarterly revenue was up 115.4% compared to the same quarter last year. During the same quarter last year, the company posted ($0.57) EPS.

What other stocks do shareholders of Juno Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Juno Therapeutics investors own include (KITE) (KITE) , bluebird bio (BLUE) , Gilead Sciences (GILD) , Puma Biotechnology (PBYI) , BioMarin Pharmaceutical (BMRN) , TherapeuticsMD (TXMD) , Incyte (INCY) , Alibaba Group (BABA) and Heritage-Crystal Clean (HCCI) .

When did Juno Therapeutics IPO?

Juno Therapeutics (JUNO) raised $153 million in an IPO on Friday, December 19th 2014. The company issued 9,300,000 shares at $15.00-$18.00 per share. Morgan Stanley, J.P. Morgan and Goldman Sachs acted as the underwriters for the IPO and Leerink Partners was co-manager.

NASDAQ:JUNO

Juno Therapeutics (JUNO) Stock Price, News & Analysis

→ Healthcare Takes A Big Step Forward With The Help Of AI (From The Bull Report) (Ad)

Free JUNO Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Today's Range: $86.96
▼
$86.96
50-Day Range: $86.96
▼
$86.96
52-Week Range: $19.62
▼
$87.01

Volume: 2 shs
Average Volume: 5.48 million shs
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get Juno Therapeutics alerts:

Ad Darwin

2024's Must-Have Guide: Master Crypto Investment Today

The cryptocurrency revolution is here with Bitcoin soaring past the $70,000 milestone—a clear indicator of the booming digital currency market. Are you prepared to navigate these exciting yet complex waters? Introducing "Navigating the Future: A Comprehensive Guide to Cryptocurrency Investments in 2024." This free digital guide is your essential resource for understanding and capitalizing on cryptocurrency investments, tailored for both newcomers and seasoned investors. (**By clicking the link you are subscribing to The Conservative Investor Newsletter and may receive up to 2 additional free bonus subscriptions. Unsubscribing is easy.)

Click here to download your crypto report

About Juno Therapeutics Stock (NASDAQ:JUNO)

Juno Therapeutics, Inc. (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Its product candidates JCAR017, JCAR014, and JCAR015, as well as an additional early stage product candidate incorporating a fully human binding domain, leverage CAR technology to target CD19, a protein expressed on the surface of almost all B cell leukemias and lymphomas. Its CAR product candidate JCAR018 targets CD22, a different protein commonly expressed on the surface of B cell leukemias and lymphomas. Its MUC-16 directed product candidate is an armored CAR that secretes the cytokine interleukin 12 (IL-12), which may help to overcome the inhibitory effects that the tumor microenvironment can have on T cell activity.

Ad Darwin

2024's Must-Have Guide: Master Crypto Investment Today

Click here to download your crypto report

JUNO Stock News Headlines

April 9, 2024 | yahoo.com

Zelda Williams did extensive 'academic study' of '80s films before helming 'Lisa Frankenstein'

March 30, 2024 | msn.com

Michigan AP names Trey McKenney of Orchard Lake St. Mary's Division 1 basketball Player of the Year

April 19, 2024 | DTI (Ad)

Start loving Mondays like this

Wouldn’t you love to start looking forward to Mondays? We’re in a New Paradigm Shift in the market that could make it possible! You see, rallies over the weekends have become much more common in the last few years. Imagine hitting a few buttons on your phone or laptop to place a quick trade before the weekend hits… And coming back on Monday to what could be extra income sitting in your account… Weekend after weekend!

March 27, 2024 | finance.yahoo.com

Xcell Biosciences Announces New Scientific and Business Advisory Board

March 18, 2024 | bizjournals.com

Out of the lab and into the factory

March 16, 2024 | seekingalpha.com

EFTR eFFECTOR Therapeutics, Inc.

March 15, 2024 | msn.com

Motorcyclist killed in fatal accident near Manatee Avenue, Bradenton police say

February 21, 2024 | msn.com

What we know about Jeff Bezos’ net worth

April 19, 2024 | Banyan Hill Publishing (Ad)

The Best AI Stock to Own in the World Today is Trading for Just $25

“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.

February 8, 2024 | uk.finance.yahoo.com

Mantle Cell Lymphoma Therapeutics Market to Reach $3.29 Billion by 2028 with Innovations in Targeted Therapies

January 31, 2024 | ca.news.yahoo.com

Zelda Williams Says She Was 'Fascinated’ by Late Dad Robin Williams' Career from Young Age

January 31, 2024 | msn.com

How Zelda Williams Found Humor in Trauma

January 16, 2024 | msn.com

Covid cases in Stoke-on-Trent right now as 'Juno' strain hits UK

January 11, 2024 | uk.finance.yahoo.com

Vaginitis Therapeutics Global Market Landscape Analysis 2023-2030: New Treatment Avenues and Key Company Innovations Propel the Industry

January 10, 2024 | finance.yahoo.com

Autolus Therapeutics announces the appointment of Robert W. Azelby to its Board of Directors

January 8, 2024 | tmcnet.com

Biotech Industry Veterans Jeff Jonas and Al Robichaud Join Cure Ventures as Partners

January 7, 2024 | seekingalpha.com

Week In Review: 2024 Kicks Off With 3 Deals Worth A Total Of $4B

December 22, 2023 | msn.com

Two dead in McDermot Avenue fire, cause under investigation

December 12, 2023 | bbc.com

Elliot Page: Juno actor to divorce Emma Portner

December 5, 2023 | finance.yahoo.com

Seattle Children's launches BrainChild Bio to accelerate CAR T-cell therapies for children with brain tumors

December 5, 2023 | finance.yahoo.com

First Patient Enrolled in the PUERTA Phase 2A ARDS Clinical Trial: Treatment with Aqualung Therapeutics ALT-100 mAb

December 4, 2023 | markets.businessinsider.com

TScan Therapeutics Expands Manufacturing Leadership with the Appointment of Justin McCue, Ph.D., as Chief Technology Officer

September 15, 2023 | tmcnet.com

Repairon Appoints Co-Founder Dr. Lothar Germeroth as Chief Executive Officer

September 12, 2023 | finance.yahoo.com

CARGO Therapeutics Announces Appointment of Michael Ports, PhD, as Chief Scientific Officer

August 28, 2023 | msn.com

Notch Therapeutics closes Vancouver lab, will focus on Toronto and Seattle offices

July 20, 2023 | msn.com

Affini-T Therapeutics shutting down Seattle lab

June 15, 2023 | finance.yahoo.com

ADC Therapeutics Announces Evolution of Board of Directors

See More Headlines

Receive JUNO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Juno Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/01/2017
Today: 4/19/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: N/A
Industry: N/A
Sub-Industry: N/A
Current Symbol: NASDAQ:JUNO
CUSIP: N/A
CIK: 1594864
Web: www.junotherapeutics.com
Phone: +1-206-5821600
Fax: N/A
Employees: N/A
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Optionable
Beta: N/A

5G Stocks: The Path Forward is Profitable

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

Howard H. Pien (Age 59)
Independent Chairman of the Board
Hans Edgar Bishop (Age 53)
President, Chief Executive Officer, Director
Sunil Agarwal M.D. (Age 47)
President of Research & Development
Steven D. Harr M.D. (Age 46)
Chief Financial Officer, Head of Corporate Development
Hyam I. Levitsky M.D (Age 54)
Executive vice president - Research, chief scientific officer
Robert W. Azelby (Age 49)
Executive Vice President, Chief Commercial Officer
Ann Lee Ph.D.
Executive Vice President - Technical Operations
Patrick Y. Yang (Age 69)
Executive Vice President
Cynthia Elkins
Chief Information Officer
Bernard J. Cassidy (Age 62)
General Counsel, Secretary

JUNO Stock Analysis - Frequently Asked Questions

How were Juno Therapeutics' earnings last quarter?: Juno Therapeutics Inc (NASDAQ:JUNO) announced its earnings results on Wednesday, November, 1st. The biopharmaceutical company reported ($0.73) EPS for the quarter, beating analysts' consensus estimates of ($0.80) by $0.07. The biopharmaceutical company had revenue of $44.80 million for the quarter, compared to analyst estimates of $18.12 million. Juno Therapeutics's quarterly revenue was up 115.4% compared to the same quarter last year. During the same quarter last year, the company posted ($0.57) EPS.
What other stocks do shareholders of Juno Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Juno Therapeutics investors own include (KITE) (KITE), bluebird bio (BLUE), Gilead Sciences (GILD), Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), TherapeuticsMD (TXMD), Incyte (INCY), Alibaba Group (BABA) and Heritage-Crystal Clean (HCCI).
When did Juno Therapeutics IPO?: Juno Therapeutics (JUNO) raised $153 million in an IPO on Friday, December 19th 2014. The company issued 9,300,000 shares at $15.00-$18.00 per share. Morgan Stanley, J.P. Morgan and Goldman Sachs acted as the underwriters for the IPO and Leerink Partners was co-manager.

This page (NASDAQ:JUNO) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Juno Therapeutics (JUNO) Stock Price, News & Analysis

About Juno Therapeutics Stock (NASDAQ:JUNO)

JUNO Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

JUNO Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info